Genetic Technologies Ltd. ADR (GENE): Price and Financial Metrics
GENE Price/Volume Stats
| Current price | $2.26 | 52-week high | $5.90 |
| Prev. close | $2.44 | 52-week low | $1.80 |
| Day low | $2.13 | Volume | 59,613 |
| Day high | $2.47 | Avg. volume | 29,333 |
| 50-day MA | $2.53 | Dividend yield | N/A |
| 200-day MA | $3.20 | Market Cap | 8.69M |
GENE Stock Price Chart Interactive Chart >
Genetic Technologies Ltd. ADR (GENE) Company Bio
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Latest GENE News From Around the Web
Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.
GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized WellnessMELBOURNE, Australia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies (GTG) is proud to provide details of a series of recent transformative initiatives. Our commitment to advancing early detection of serious diseases through a revolutionary non-invasive saliva test has been recently showcased on several national Australian media channels. These segments highlight geneType's potential to shape the future of proactive health management. Precision Medicine Takes Flight at Gold Coast Private |
Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio ChangeMELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect: (i) a share consolidation of its ordinary shares (the “Shares”) of one (1) for one hundred (100) existing Shares (the “Local Consolidation”) and (ii) a change of ratio in the Company’s American Depositary Share (“ADS”) program, comprising a change in th |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning! |
Here's Why Shareholders May Want To Be Cautious With Increasing Genetic Technologies Limited's (ASX:GTG) CEO Pay PacketKey Insights Genetic Technologies to hold its Annual General Meeting on 21st of November Total pay for CEO Simon... |
Gene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical TrialMELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide an update on the company activities for the quarter ending 30 September 2023. Highlights: Partnership signed with the Gold Coast Private Hospital (a member of Healthscope), to establish a Precision Medicine Clinic at the hospital.GeneType Multi-Test |
GENE Price Returns
| 1-mo | -16.00% |
| 3-mo | 21.51% |
| 6-mo | -38.53% |
| 1-year | -60.00% |
| 3-year | -88.07% |
| 5-year | -85.88% |
| YTD | -5.83% |
| 2023 | -48.39% |
| 2022 | -50.53% |
| 2021 | -47.78% |
| 2020 | 80.90% |
| 2019 | -9.54% |
Continue Researching GENE
Want to see what other sources are saying about Genetic Technologies Ltd's financials and stock price? Try the links below:Genetic Technologies Ltd (GENE) Stock Price | Nasdaq
Genetic Technologies Ltd (GENE) Stock Quote, History and News - Yahoo Finance
Genetic Technologies Ltd (GENE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...